|Table of Contents|

Short-term efficacy of camrelizumab in adjuvant chemotherapy for patients with advanced NSCLC and the influence on cellular immunity,serum tumor markers

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 06
Page:
1047-1051
Research Field:
Publishing date:

Info

Title:
Short-term efficacy of camrelizumab in adjuvant chemotherapy for patients with advanced NSCLC and the influence on cellular immunity,serum tumor markers
Author(s):
XU Judi; HUANG Qian; YANG Zhiyong; LIU Hedai; NI Guoying; HUANG Yan; HUANG Ying
Department of Oncology,Chongming Branch of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 202150,China.
Keywords:
camrelizumab; non-small cell lung cancer; chemotherapy; cellular immunity
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.06.012
Abstract:
Objective：To observe the short-term efficacy of camrelizumab in adjuvant chemotherapy for patients with advanced non-small cell lung cancer (NSCLC),and the influence on cellular immunity,serum cytokeratin 19 fragment (CYFRA21-1),angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).Methods:A total of 102 patients with advanced NSCLC admitted to the hospital from January 2018 to December 2020 were selected,and randomly divided into combination group and control group,with 51 cases in each group.Patients in the control group were treated with chemotherapy,and those in the combination group were treated with camrelizumab on this basis.The two groups were compared in terms of short-term efficacy,cellular immune function (NK,CD3+ and CD4+/CD8+),serum tumor markers ［CYFRA21-1,carcinoembryonic antigen (CEA),cancer antigen 125 (CA125) and nerve-specific enolase (NSE)］ and angiogenesis indicators (Ang-2 and VEGF).Results:The total clinical effective rate of treatment in the combined group (64.706%) was significantly higher than that in the control group (33.333%) (P＜0.05).After treatment,the levels of NK,CD3+,CD4+ and CD4+/CD8+ were decreased in the two groups,but higher in the combination group than in the control group (P＜0.05).The levels of CYFRA21-1,CEA,CA125 and NSE were decreased in the two groups,and lower in the combination group than in the control group (P＜0.05).The levels of Ang-2 and VEGF were decreased in the two groups.The levels of Ang-2 and VEGF in the combined group were (1 194.07±156.37) pg/mL and (308.77±107.66) pg/mL,significantly lower than (1 266.34±146.17) pg/mL and (355.74±119.38) pg/mL in the control group (P＜0.05).Conclusion:Camrelizumab used for adjuvant chemotherapy can reduce the impact on immune function in patients with advanced NSCLC,significantly improve the levels of serum tumor markers and inhibit angiogenesis to a certain extent.

References:

［1］ 凌丰宇,李明,陈青娟,等.贝伐珠单抗联合第一代表皮生长因子受体-酪氨酸激酶抑制剂一线治疗EGFR基因突变阳性晚期非小细胞肺癌的Meta分析［J］.肿瘤,2020,40(05):339-347. LING FY,LI M,CHEN QJ,et al.Efficacy and safety of bevacizumab combined with first-generation EGFR-TKI in the first-line treatment of EGFR-mutated advanced non-small cell lung cancer:A Meta-analysis［J］.Tumor,2020,40(05):339-347.
［2］ 姜桔红,李玉勤,顾莹莹.晚期非小细胞肺癌免疫检查点抑制剂相关性肌炎的临床病理学特征［J］.中华结核和呼吸杂志,2022,45(01):47-52. JIANG JH,LI YQ,GU YY.Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer［J］.Chinese Journal of Tuberculosis and Respiratory Diseases,2022,45(01):47-52.
［3］ DUMA N,SANTANA-DAVILA R,MOLINA JR.Non-small cell lung cancer:Epidemiology,screening,diagnosis,and treatment［J］.Mayo Clinic Proceedings,2019,94(8):1623-1640.
［4］ 孙鑫,门玉,惠周光.Ⅲa－N2期非小细胞肺癌新辅助治疗的研究现状［J］.中华放射肿瘤学杂志,2020,1(01):61-64. SUN X,MEN Y,HUI ZG.Research progress onneoadjuvant therapy in stage Ⅲa-N2 non-small cell lung cancer［J］.Chinese Journal of Radiation Oncology,2020,1(01):61-64.
［5］ 付群.PDCD5、NRP1表达与NSCLC患者化疗效果及预后的关系［J］.实用癌症杂志,2021,36(06):884-887. FU Q.Relationship between the expression of PDCD5 and NRP1 and the effect and prognosis of chemotherapy in NSCLC patients［J］.The Practical Journal of Cancer,2021,36(06):884-887.
［6］ BRODERICK SR.Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer［J］.Thoracic Surgery Clinics,2020,30(2):215-220.
［7］ YAN Z,YAO ZH,YAO SN,et al.Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma［J］.Immunotherapy,2020,12(4):1161-1166.
［8］ 李方,侯晓明,刘峥.同步推量调强放疗联合卡瑞利珠单抗治疗非小细胞肺癌的临床疗效及其机制研究［J］.实用心脑肺血管病杂志,2021,29(11):96-101. LI F,HOU XM,LIU Z.Clinical efficacy and mechanism of simultaneous modulated accelerated radiotherapy combined with carrelizumab in the treatment of non-small cell lung cancer［J］.Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease,2021,29(11):96-101.
［9］ 国医师协会肿瘤医师分会，中国抗癌协会肿瘤临床化疗专业委员会．中国埃克替尼治疗非小细胞肺癌专家共识(2015版)［J］.中国肺癌杂志,2015,18(7):397-400． Oncologist Branch of Chinese Medical Doctor Association,Specialized Committee of Clinical Chemotherapy of Chinese Anti-Cancer Association.China experts consensus on icotinib for non-small cell lung cancer treatment(2015 version)［J］.Chinese Journal of Lung Cancer,2015,18(7):397-400．
［10］ 林吉兴,梁朝阳,王柏霖,等.开胸或胸腔镜亚肺叶切除术治疗Ⅰ期非小细胞肺癌疗效比较［J］.海南医学,2017,28(14):2268-2270. LIN JX,LIANG CY,WANG BL,et al.Comparative study between open operation and thoracoscopic sublobar resection in the treatment of patients with stage Ⅰ non-small cell lung cancer［J］.Hainan Medical Journal,2017,28(14):2268-2270.
［11］ 朱露莎,王松华,李进冬.卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的效果及安全性的真实世界研究［J］.中国医药导报,2021,18(35):110-116. ZHU LS,WANG SH,LI JD.Real-world study of the efficacy and safety of Carrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer［J］.China Medical Herald,2021,18(35):110-116.
［12］ 戴丽,王小华,杨万春,等.贝伐珠单抗联合TP化疗方案对晚期非鳞癌非小细胞肺癌患者免疫功能、生活质量和血清肿瘤标志物的影响［J］.现代生物医学进展,2021,21(11):2174-2178. DAI L,WANG XH,YANG WC,et al.Effect of bevacizumab combined with TP chemotherapy on immune function,quality of life and serum tumor markers in patients with advanced non-small cell lung cancer［J］.Progress in Modern Biomedicine,2021,21(11):2174-2178.
［13］ 李陶威,马天江,张耀勇,等.重组人血管内皮抑制素联合贝伐珠单抗治疗中晚期非小细胞肺癌的疗效及对血清CEA、CYFRA21-1和VEGF水平的影响［J］.实用癌症杂志,2021,36(8):1309-1312. LI TW,MA TJ,ZHANG YY,et al.Efficacy of recombinant human endostatin injection combined with bevacizumab in the treatment of advanced non-small cell lung cancer and its effect on serum CEA,CYFRA21-1 and VEGF levels［J］.The Practical Journal of Cancer,2021,36(8):1309-1312.
［14］ 李岩,黎海亮,陈呈世,等.局部介入联合卡瑞利珠单抗与阿帕替尼治疗转移性软组织肉瘤的安全性和有效性［J］.介入放射学杂志,2021,30(11):1123-1127. LI Y,LI HL,CHEN CS,et al.Local intervention combined with camrelizumab and apatinib for the treatment of metastatic soft tissue sarcoma:analysis of its safety and curative effectiveness［J］.Journal of Interventional Radiology,2021,30(11):1123-1127.
［15］ 吴丽明,金鹿,马继明,等.华蟾素胶囊、依托泊苷联合顺铂治疗老年非小细胞肺癌对患者炎症因子、血清肿瘤标志物的影响［J］.海南医学,2020,31(1):20-23. WU LM,JIN L,MA JM,et al.Effect of Huachansu capsule plus etoposide combined with cisplatin on inflammatory factors and serum tumor markers in elderly patients with non-small-cell lung cancer［J］.Hainan Medical Journal,2020,31(1):20-23.

Memo

Memo:
-
Last Update: 1900-01-01